Eye phototherapy mask meibomask®

Overview
A clinical solution leveraging LM™ LLLT photobiomodulation to manage anterior-segment and ocular-surface conditions including Dry Eye Disease (DED), Meibomian Gland Dysfunction (MGD), chalazion and blepharitis. Designed for full-coverage eyelid therapy with adjustable dosing according to patient needs.

Benefits

• COMPLETE AND DIRECT TREATMENT: Delivers therapy to both upper and lower eyelids to target MGD-related DED and other anterior-segment conditions.
• TOTALLY NON-INVASIVE: Uses medically certified near-infrared emission applied on the skin to induce endogenous heating and cellular stimulation without surgical intervention.
• QUICK AND EFFECTIVE CLINICAL RESPONSE: Patients commonly report symptomatic relief within ~15 minutes after a session.
• OPERATOR-FRIENDLY: Minimal training and no time-consuming setup required, enabling efficient clinic workflow.

About LM™ LLLT (Light Modulation™ Low Level Light Therapy)
Patented photobiomodulation technology that stimulates mitochondrial activity, triggering biochemical responses that support protein synthesis and eyelid gland function. Near-infrared emission contributes to an increased and stabilized tear lipid layer. meibomask® integrates with me-check® screening to tailor energy dose and treatment duration to MGD severity.

Clinical feedback
Practitioners report reduced patient discomfort and improved tear production following LM™ LLLT sessions delivered via meibomask® (testimonial reference: Prof. G. Giannaccare, MD).

Technical specifications

• Technology: LM™ LLLT (patented photobiomodulation)
• Indications: Dry Eye Disease (DED), Meibomian Gland Dysfunction (MGD), chalazion, blepharitis and other anterior-segment / ocular surface conditions
• Application: Full therapy covering both upper and lower eyelids
• Modality: Non-invasive near-infrared emission at a medically certified wavelength
• Physiological effect: Endogenous heating; stimulation of cellular ATP production; increased and stabilized tear lipid layer
• Treatment time / response: Symptomatic relief commonly reported within ~15 minutes
• Customization: Energy dose and treatment duration adjusted according to MGD severity (integration with me-check® screening)
• Operator requirements: Minimal training, no setup time
• Design: Matches industrial design family of other Espansione solutions